JPWO2020101740A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020101740A5 JPWO2020101740A5 JP2021526563A JP2021526563A JPWO2020101740A5 JP WO2020101740 A5 JPWO2020101740 A5 JP WO2020101740A5 JP 2021526563 A JP2021526563 A JP 2021526563A JP 2021526563 A JP2021526563 A JP 2021526563A JP WO2020101740 A5 JPWO2020101740 A5 JP WO2020101740A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- protein
- scaffold protein
- biologically active
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710006307 MVA110L Proteins 0.000 claims description 40
- 101710042748 UL80 Proteins 0.000 claims description 40
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 19
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007172 antigens Proteins 0.000 claims description 14
- 102000038129 antigens Human genes 0.000 claims description 14
- 210000004027 cells Anatomy 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- -1 CD86 Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 231100000765 Toxin Toxicity 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 108020003112 toxins Proteins 0.000 claims description 6
- 102100009534 TNF Human genes 0.000 claims description 5
- 101710040537 TNF Proteins 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 101710012053 CD274 Proteins 0.000 claims description 4
- 102100007290 CD274 Human genes 0.000 claims description 4
- 102100019451 CD80 Human genes 0.000 claims description 4
- 101700080477 CD80 Proteins 0.000 claims description 4
- 102000002698 KIR Receptors Human genes 0.000 claims description 4
- 108010043610 KIR Receptors Proteins 0.000 claims description 4
- 108060004270 LAG3 Proteins 0.000 claims description 4
- 102100017213 LAG3 Human genes 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 4
- 102100019764 PDCD1 Human genes 0.000 claims description 4
- 102100007289 PDCD1LG2 Human genes 0.000 claims description 4
- 101710011976 PDCD1LG2 Proteins 0.000 claims description 4
- 108060007796 SPATA2 Proteins 0.000 claims description 4
- 108091008153 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 101710026335 TP53 Proteins 0.000 claims description 4
- 102100019730 TP53 Human genes 0.000 claims description 4
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 4
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase family Human genes 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase family Proteins 0.000 claims description 4
- 239000002555 ionophore Substances 0.000 claims description 4
- 230000000236 ionophoric Effects 0.000 claims description 4
- GIYXAJPCNFJEHY-UHFFFAOYSA-N methyl-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]azanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 4
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
- 102100006047 TIGIT Human genes 0.000 claims description 3
- 101700052319 TIGIT Proteins 0.000 claims description 3
- 101710038603 TNFRSF18 Proteins 0.000 claims description 3
- 102100003096 TNFRSF18 Human genes 0.000 claims description 3
- 230000003000 nontoxic Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 101710039842 ADORA2A Proteins 0.000 claims description 2
- 102100016549 ANPEP Human genes 0.000 claims description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 2
- 206010059512 Apoptosis Diseases 0.000 claims description 2
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 claims description 2
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 claims description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 2
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 claims description 2
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 claims description 2
- 102100015340 CAMLG Human genes 0.000 claims description 2
- 101700063813 CAMLG Proteins 0.000 claims description 2
- 101710024418 CD101 Proteins 0.000 claims description 2
- 102100018947 CD101 Human genes 0.000 claims description 2
- 108010049990 CD13 Antigens Proteins 0.000 claims description 2
- 101700056583 CD27 Proteins 0.000 claims description 2
- 102100019459 CD27 Human genes 0.000 claims description 2
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 102100019461 CD28 Human genes 0.000 claims description 2
- 101700033362 CD28 Proteins 0.000 claims description 2
- 102100013077 CD4 Human genes 0.000 claims description 2
- 101700022938 CD4 Proteins 0.000 claims description 2
- 101710040446 CD40 Proteins 0.000 claims description 2
- 102100013137 CD40 Human genes 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100003729 CD40LG Human genes 0.000 claims description 2
- 102100005830 CD70 Human genes 0.000 claims description 2
- 102100008191 CD8A Human genes 0.000 claims description 2
- 101700054655 CD8A Proteins 0.000 claims description 2
- 101710011595 DPT Proteins 0.000 claims description 2
- 102000003425 EC 1.14.18.1 Human genes 0.000 claims description 2
- 108060008724 EC 1.14.18.1 Proteins 0.000 claims description 2
- 101710038596 EDA2R Proteins 0.000 claims description 2
- 102100013113 EDA2R Human genes 0.000 claims description 2
- 101710011427 ENTPD1 Proteins 0.000 claims description 2
- 102100009509 ENTPD1 Human genes 0.000 claims description 2
- 101700025368 ERBB2 Proteins 0.000 claims description 2
- 102100016662 ERBB2 Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 210000001808 Exosomes Anatomy 0.000 claims description 2
- 102100003082 FASLG Human genes 0.000 claims description 2
- 101700010580 FLO11 Proteins 0.000 claims description 2
- 101700036477 FOLH1 Proteins 0.000 claims description 2
- 102100008453 FOLH1 Human genes 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- 101710039212 ICOSLG Proteins 0.000 claims description 2
- 102100014733 ICOSLG Human genes 0.000 claims description 2
- 101700051007 IGSF3 Proteins 0.000 claims description 2
- 102100018946 IGSF3 Human genes 0.000 claims description 2
- 102100008123 IGSF8 Human genes 0.000 claims description 2
- 101700021096 IGSF8 Proteins 0.000 claims description 2
- 101710006711 ITGA4 Proteins 0.000 claims description 2
- 102100019334 ITGA4 Human genes 0.000 claims description 2
- 102100001478 ITGB1 Human genes 0.000 claims description 2
- 101710006661 ITGB1 Proteins 0.000 claims description 2
- 101710006663 ITGB2 Proteins 0.000 claims description 2
- 102100001475 ITGB2 Human genes 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102100013180 KDR Human genes 0.000 claims description 2
- 102100011847 LTB Human genes 0.000 claims description 2
- 101710040539 LTB Proteins 0.000 claims description 2
- 210000000265 Leukocytes Anatomy 0.000 claims description 2
- 102100000165 MS4A1 Human genes 0.000 claims description 2
- 101710010909 MS4A1 Proteins 0.000 claims description 2
- 102100006037 MUC1 Human genes 0.000 claims description 2
- 101700052761 MUC1 Proteins 0.000 claims description 2
- 102100006044 MUC16 Human genes 0.000 claims description 2
- 101700008449 MUC16 Proteins 0.000 claims description 2
- 101710038602 NGFR Proteins 0.000 claims description 2
- 102100008795 NGFR Human genes 0.000 claims description 2
- 101710039712 NT5E Proteins 0.000 claims description 2
- 102100017063 NT5E Human genes 0.000 claims description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 2
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 2
- 101700008337 PSMA Proteins 0.000 claims description 2
- 102100004359 PTGFRN Human genes 0.000 claims description 2
- 101710021351 PTGFRN Proteins 0.000 claims description 2
- 102100005499 PTPRC Human genes 0.000 claims description 2
- 101700059076 PTPRC Proteins 0.000 claims description 2
- 101710037934 QRSL1 Proteins 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 101710045176 SIVA1 Proteins 0.000 claims description 2
- 102100013834 SLC3A2 Human genes 0.000 claims description 2
- 108091006293 SLC3A2 Proteins 0.000 claims description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 2
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims description 2
- 102000007193 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 2
- 108010008478 TNF-Related Apoptosis-Inducing Ligand Proteins 0.000 claims description 2
- 102100012981 TNFRSF10A Human genes 0.000 claims description 2
- 101710030971 TNFRSF10A Proteins 0.000 claims description 2
- 101710030970 TNFRSF10B Proteins 0.000 claims description 2
- 102100012980 TNFRSF10B Human genes 0.000 claims description 2
- 101710030969 TNFRSF10C Proteins 0.000 claims description 2
- 102100012977 TNFRSF10C Human genes 0.000 claims description 2
- 101710030968 TNFRSF10D Proteins 0.000 claims description 2
- 102100011904 TNFRSF10D Human genes 0.000 claims description 2
- 101710030909 TNFRSF13B Proteins 0.000 claims description 2
- 102100008790 TNFRSF14 Human genes 0.000 claims description 2
- 101710038601 TNFRSF14 Proteins 0.000 claims description 2
- 102100008794 TNFRSF17 Human genes 0.000 claims description 2
- 101710038604 TNFRSF17 Proteins 0.000 claims description 2
- 101710038571 TNFRSF19 Proteins 0.000 claims description 2
- 101710038526 TNFRSF1A Proteins 0.000 claims description 2
- 102100003095 TNFRSF1A Human genes 0.000 claims description 2
- 101710038524 TNFRSF1B Proteins 0.000 claims description 2
- 102100003105 TNFRSF1B Human genes 0.000 claims description 2
- 102100003106 TNFRSF21 Human genes 0.000 claims description 2
- 101710008042 TNFRSF21 Proteins 0.000 claims description 2
- 101710038599 TNFRSF21 Proteins 0.000 claims description 2
- 101710038569 TNFRSF25 Proteins 0.000 claims description 2
- 101710040448 TNFRSF4 Proteins 0.000 claims description 2
- 102100013135 TNFRSF4 Human genes 0.000 claims description 2
- 102100009560 TNFRSF6B Human genes 0.000 claims description 2
- 101710022317 TNFRSF6B Proteins 0.000 claims description 2
- 101710040533 TNFRSF8 Proteins 0.000 claims description 2
- 102100009538 TNFRSF8 Human genes 0.000 claims description 2
- 102100009537 TNFRSF9 Human genes 0.000 claims description 2
- 101710040535 TNFRSF9 Proteins 0.000 claims description 2
- 102100002202 TNFSF12 Human genes 0.000 claims description 2
- 101710022356 TNFSF12 Proteins 0.000 claims description 2
- 102100009493 TNFSF13B Human genes 0.000 claims description 2
- 101710004627 TNFSF13B Proteins 0.000 claims description 2
- 101710022241 TNFSF15 Proteins 0.000 claims description 2
- 102100002239 TNFSF15 Human genes 0.000 claims description 2
- 102100011846 TNFSF4 Human genes 0.000 claims description 2
- 102100003083 TNFSF8 Human genes 0.000 claims description 2
- 101710025687 TNFSF8 Proteins 0.000 claims description 2
- 102100003084 TNFSF9 Human genes 0.000 claims description 2
- 101700054742 TRAM1 Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims description 2
- 108091007928 VEGF receptors Proteins 0.000 claims description 2
- 101710036075 VSIR Proteins 0.000 claims description 2
- 102100015314 VSIR Human genes 0.000 claims description 2
- 101700081164 ZBED1 Proteins 0.000 claims description 2
- 102000004965 antibodies Human genes 0.000 claims description 2
- 108090001123 antibodies Proteins 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000020411 cell activation Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims description 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims description 2
- 108010052621 fas Receptor Proteins 0.000 claims description 2
- 102000018823 fas Receptor Human genes 0.000 claims description 2
- 230000001605 fetal Effects 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037240 fusion proteins Human genes 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000003735 mesothelin Human genes 0.000 claims description 2
- 108090000015 mesothelin Proteins 0.000 claims description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 229920000023 polynucleotide Polymers 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 102000003995 transcription factors Human genes 0.000 claims description 2
- 108090000464 transcription factors Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 102100015697 NTF3 Human genes 0.000 claims 1
- 101700009327 NTF3 Proteins 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 101700044827 RNMT Proteins 0.000 claims 1
- 102100008791 TNFRSF12A Human genes 0.000 claims 1
- 102100009744 TNFRSF13B Human genes 0.000 claims 1
- 102100003097 TNFRSF19 Human genes 0.000 claims 1
- 102100003107 TNFRSF25 Human genes 0.000 claims 1
- 108010014401 TWEAK Receptor Proteins 0.000 claims 1
- 230000000139 costimulatory Effects 0.000 claims 1
- 102000025599 immune receptors Human genes 0.000 claims 1
- 108091008191 immune receptors Proteins 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 19
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 11
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 108060000868 BASP1 Proteins 0.000 description 1
- 102100000872 BASP1 Human genes 0.000 description 1
- 102100001891 CTAG1A Human genes 0.000 description 1
- 101710004449 CTAG1A Proteins 0.000 description 1
- 101710004393 HAVCR2 Proteins 0.000 description 1
- 102100016384 HAVCR2 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101710022243 TNFSF18 Proteins 0.000 description 1
- 102100014338 ZNF654 Human genes 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Description
図面は、例示のみを目的として本開示の様々な態様を示す。当業者は、本明細書に例示される構造及び方法の代替的な態様が、本明細書に記載される本開示の原理から逸脱することなく用いられ得ることを以下の考察から容易に認識するであろう。
本発明の実施形態において、例えば以下の項目が提供される。
(項目1)
足場タンパク質に連結した生物学的に活性な分子を含む単離された細胞外小胞(EV)であって、前記足場タンパク質はN末端ドメイン(ND)及びエフェクタードメイン(ED)を含み、前記NDは前記EVの内腔表面と会合し、前記EDはイオン相互作用によって前記EVの前記内腔表面と会合し、前記EDは配列中に少なくとも2つの連続したリジン(Lys)を含む、前記単離された細胞外小胞(EV)。
(項目2)
前記NDが、ミリストイル化を介して前記EVの前記内腔表面と会合する、項目1に記載のEV。
(項目3)
前記NDが、N末端にGlyを有する、項目2に記載のEV。
(項目4)
前記EDが、少なくとも3つのLys、少なくとも4つのLys、少なくとも5つのLys、少なくとも6つのLys、または少なくとも7つのLysを含む、項目1~3のいずれか一項に記載のEV。
(項目5)
前記EDが、ペプチド結合によって前記NDに連結される、項目1~4のいずれか一項に記載のEV。
(項目6)
前記EDが、(Lys)nを含み、nが1~10の整数である、項目4または5に記載のEV。
(項目7)
前記EDが、KK、KKK、KKKK(配列番号151)、KKKKK(配列番号152)、またはそれらの任意の組み合わせを含む、項目1~6のいずれか一項に記載のEV。
(項目8)
前記NDが、G:X2:X3:X4:X5:X6に記載されるアミノ酸配列を含み、GがGlyとして表されるグリシンであり、「:」がペプチド結合を表し、前記X2~前記X6のそれぞれが独立してアミノ酸であり、前記X6が塩基性アミノ酸を含む、項目1~7のいずれか一項に記載のEV。
(項目9)
前記X6が、Lys、Arg、及びHisからなる群から選択される、項目8に記載のEV。
(項目10)
足場タンパク質に連結した生物学的に活性な分子を含む単離された細胞外小胞(EV)であって、前記足場タンパク質はN末端ドメイン(ND)及びエフェクタードメイン(ED)を含み、前記NDはG:X2:X3:X4:X5:X6に記載のアミノ酸配列を含み、GはGlyによって表されるグリシンであり、「:」はペプチド結合を表し、前記X2~前記X6のそれぞれは独立してアミノ酸であり、前記X6は塩基性アミノ酸を含み、前記EDはペプチド結合によってX6に連結され、前記EDのN末端に少なくとも1つのリジンを含む、前記単離された細胞外小胞(EV)。
(項目11)
前記EDが、ウイルスの膜貫通ドメインまたは細胞質ドメインを含まない、項目1~10のいずれか一項に記載のEV。
(項目12)
前記X2が、Pro、Gly、Ala、及びSerからなる群から選択される、項目8~11のいずれか一項に記載のEV。
(項目13)
前記X4が、Pro、Gly、Ala、Ser、Val、Ile、Leu、Phe、Trp、Tyr、Gln、及びMetからなる群から選択される、項目8~12のいずれか一項に記載のEV。
(項目14)
前記X5が、Pro、Gly、Ala、及びSerからなる群から選択される、項目8~13のいずれか一項に記載のEV。
(項目15)
前記足場タンパク質の前記NDが、G:X2:X3:X4:X5:X6のアミノ酸配列を含み、
(i)Gが、Glyを表し、
(ii)「:」が、ペプチド結合を表し、
(iii)前記X2が、Pro、Gly、Ala、及びSerからなる群から選択されるアミノ酸であり、
(iv)前記X3が、アミノ酸であり、
(v)前記X4が、Pro、Gly、Ala、Ser、Val、Ile、Leu、Phe、Trp、Tyr、Gln、及びMetからなる群から選択されるアミノ酸であり、
(vi)前記X5が、Pro、Gly、Ala、及びSerからなる群から選択されるアミノ酸であり、
(vii)前記X6が、Lys、Arg、及びHisからなる群から選択されるアミノ酸である、項目1~14のいずれか一項に記載のEV。
(項目16)
前記X3が、Asn、Gln、Ser、Thr、Asp、Glu、Lys、His、及びArgからなる群から選択される、項目8~15のいずれか一項に記載のEV。
(項目17)
前記ND及び前記EDが、リンカーによって接合される、項目1~9及び11~16のいずれか一項に記載のEV。
(項目18)
前記リンカーが、ペプチド結合または1つ以上のアミノ酸を含む、項目17に記載のEV。
(項目19)
足場タンパク質に連結した生物学的に活性な分子を含む単離された細胞外小胞(EV)であって、前記足場タンパク質はND-EDを含み、
a.NDはG:X2:X3:X4:X5:X6を含み、
i.GはGlyを表し、
ii.「:」はペプチド結合を表し、
iii.前記X2はPro、Gly、Ala、及びSerからなる群から選択されるアミノ酸であり、
iv.前記X3はアミノ酸であり、
v.前記X4はPro、Gly、Ala、Ser、Val、Ile、Leu、Phe、Trp、Tyr、Glu、及びMetからなる群から選択されるアミノ酸であり、
vi.前記X5はPro、Gly、Ala、及びSerからなる群から選択されるアミノ酸であり、
vii.前記X6はLys、Arg、及びHisからなる群から選択されるアミノ酸であり、
b.「-」は1つ以上のアミノ酸を含む任意のリンカーであり、
c.EDは(i)ペプチド結合もしくは1つ以上のアミノ酸によって前記X6に連結される少なくとも2つの連続するリジン(Lys)、または(ii)ペプチド結合によって前記X6に直接連結される少なくとも1つのリジンを含むエフェクタードメインである、前記単離された細胞外小胞(EV)。
(項目20)
前記X2が、Gly及びAlaからなる群から選択される、項目8~19のいずれか一項に記載のEV。
(項目21)
前記X3が、Lysである、項目8~20のいずれか一項に記載のEV。
(項目22)
前記X4が、LeuまたはGluである、項目8~21のいずれか一項に記載のEV。
(項目23)
前記X5が、Ser及びAlaからなる群から選択される、項目8~22のいずれか一項に記載のEV。
(項目24)
前記X6がLysである、項目8~23のいずれか一項に記載のEV。
(項目25)
前記X2が、Gly、Ala、またはSerであり、前記X3が、LysまたはGluであり、前記X4が、Leu、Phe、Ser、及びGluであり、前記X5が、SerまたはAlaであり、前記X6が、Lysである、項目8~24のいずれか一項に記載のEV。
(項目26)
前記ND及び前記EDが、1つ以上のアミノ酸を含むリンカーによって連結される、項目19~25のいずれか一項に記載のEV。
(項目27)
前記EDが、Lys(K)、KK、KKK、KKKK(配列番号151)、KKKKK(配列番号152)、またはそれらの任意の組み合わせを含む、項目19~26のいずれか一項に記載のEV。
(項目28)
前記足場タンパク質が、(i)GGKLSKK(配列番号157)、(ii)GAKLSKK(配列番号158)、(iii)GGKQSKK(配列番号159)、(iv)GGKLAKK(配列番号160)、または(v)それらの任意の組み合わせからなる群から選択されるアミノ酸配列を含む、項目1~27のいずれか一項に記載のEV。
(項目29)
前記足場タンパク質が、(i)GGKLSKKK(配列番号161)、(ii)GGKLSKKS(配列番号162)、(iii)GAKLSKKK(配列番号163)、(iv)GAKLSKKS(配列番号164)、(v)GGKQSKKK(配列番号165)、(vi)GGKQSKKS(配列番号166)、(vii)GGKLAKKK(配列番号167)、(viii)GGKLAKKS(配列番号168)、及び(ix)それらの任意の組み合わせからなる群から選択されるアミノ酸配列を含む、項目28に記載のEV。
(項目30)
前記足場タンパク質が、少なくとも約8、少なくとも約9、少なくとも約10、少なくとも約11、少なくとも約12、少なくとも約13、少なくとも約14、少なくとも約15、少なくとも約16、少なくとも約17、少なくとも約18、少なくとも約19、少なくとも約20、少なくとも約21、少なくとも約22、少なくとも約23、少なくとも約24、少なくとも約25、少なくとも約30、少なくとも約35、少なくとも約40、少なくとも約45、少なくとも約50、少なくとも約55、少なくとも約60、少なくとも約65、少なくとも約70、少なくとも約75、少なくとも約80、少なくとも約85、少なくとも約90、少なくとも約95、少なくとも約100、少なくとも約105、少なくとも約110、少なくとも約120、少なくとも約130、少なくとも約140、少なくとも約150、少なくとも約160、少なくとも約170、少なくとも約180、少なくとも約190、または少なくとも約200アミノ酸長である、項目1~29のいずれか1項に記載のEV。
(項目31)
前記足場タンパク質が、(i)GGKLSKKKKGYNVN(配列番号169)、(ii)GAKLSKKKKGYNVN(配列番号170)、(iii)GGKQSKKKKGYNVN(配列番号171)、(iv)GGKLAKKKKGYNVN(配列番号172)、(v)GGKLSKKKKGYSGG(配列番号173)、(vi)GGKLSKKKKGSGGS(配列番号174)、(vii)GGKLSKKKKSGGSG(配列番号175)、(viii)GGKLSKKKSGGSGG(配列番号176)、(ix)GGKLSKKSGGSGGS(配列番号177)、(x)GGKLSKSGGSGGSV(配列番号178)、または(xi)GAKKSKKRFSFKKS(配列番号179)を含む、項目1~30のいずれか一項に記載のEV。
(項目32)
前記足場タンパク質が、N末端にMetを含まない、項目1~31のいずれか一項に記載のEV。
(項目33)
前記足場タンパク質が、前記足場タンパク質の前記N末端にミリストイル化アミノ酸残基を含む、項目1~32のいずれか一項に記載のEV。
(項目34)
前記足場タンパク質の前記N末端における前記アミノ酸残基が、Glyである、項目33に記載のEV。
(項目35)
前記足場タンパク質の前記N末端における前記アミノ酸残基が、合成物質である、項目33または34に記載のEV。
(項目36)
前記足場タンパク質の前記N末端における前記アミノ酸残基が、グリシン類似体である、項目33または35に記載のEV。
(項目37)
前記足場タンパク質が、配列番号1(MARKS)、配列番号2(MARCKSL1)、または配列番号3(BASP1)と少なくとも約70%、少なくとも約75%、少なくとも約80%、少なくとも約85%、少なくとも約90%、少なくとも約95%、少なくとも約96%、少なくとも約97%、少なくとも約98%、少なくとも約99%、または約100%の配列同一性を有するアミノ酸配列を含む、項目1~36のいずれか1項に記載のEV。
(項目38)
前記生物学的に活性な分子が、前記EVの前記内腔表面または内腔上にある、項目1~37のいずれか一項に記載のEV。
(項目39)
前記足場タンパク質が、膜貫通ドメインをさらに含む、項目1及び8のいずれか一項に記載のEV。
(項目40)
前記膜貫通ドメインが、前記足場タンパク質のEDドメインと前記生物学的に活性な分子との間にある、項目39に記載のEV。
(項目41)
前記足場タンパク質が、小胞外ドメインをさらに含む、項目1~40のいずれか一項に記載のEV。
(項目42)
前記生物学的に活性な分子が、前記小胞外ドメインに連結される、項目41に記載のEV。
(項目43)
前記足場タンパク質が、リンカーによって前記生物学的に活性な分子に連結される、項目1~42のいずれか一項に記載のEV。
(項目44)
NDドメインが、リンカーによってEDドメインに連結される、項目1~43のいずれか一項に記載のEV。
(項目45)
前記リンカーが、ペプチド結合または1つ以上のアミノ酸を含む、項目43または44に記載のEV。
(項目46)
前記リンカーが、切断可能なリンカーを含む、項目17~19、26、及び43~45のいずれか一項に記載のEV。
(項目47)
前記リンカーが、柔軟なリンカーを含む、項目17~19、26、及び43~45のいずれか一項に記載のEV。
(項目48)
前記生物学的に活性な分子が、タンパク質、ポリペプチド、ペプチド、ポリヌクレオチド(DNA及び/またはRNA)、化学化合物、ウイルス、イオノフォア、イオノフォア用担体、チャネルもしくは細孔を形成する部分、またはそれらの任意の組み合わせを含む、項目1~47のいずれか一項に記載のEV。
(項目49)
前記タンパク質が、組換えペプチド、天然ペプチド、合成ペプチド、抗体、融合タンパク質、またはそれらの任意の組み合わせを含む、項目48に記載のEV。
(項目50)
前記タンパク質が、酵素、サイトカイン、リガンド、受容体、転写因子、またはそれらの組み合わせを含む、項目48に記載のEV。
(項目51)
前記ウイルスが、アデノ随伴ウイルス、パルボウイルス、レトロウイルス、アデノウイルス、またはそれらの任意の組み合わせを含む、項目48に記載のEV。
(項目52)
前記EVが、第2の足場タンパク質をさらに含む、項目1~51のいずれか一項に記載のEV。
(項目53)
前記第2の足場タンパク質が、PTGFRNポリペプチド、BSGポリペプチド、IGSF2ポリペプチド、IGSF3ポリペプチド、IGSF8ポリペプチド、ITGB1ポリペプチド、ITGA4ポリペプチド、SLC3A2ポリペプチド、ATPトランスポーターポリペプチド、アミノペプチダーゼN(ANPEP)ポリペプチド、エクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼファミリーメンバー1(ENPP1)ポリペプチド、ネプリライシン(MME)ポリペプチド、ニューロピリン-1(NRP1)ポリペプチド、またはそれらの断片を含む、項目52に記載のEV。
(項目54)
前記生物学的に活性な分子が、負のチェックポイント調節因子の阻害剤または負のチェックポイント調節因子の結合パートナーの阻害剤である、項目1~53のいずれか1項に記載のEV。
(項目55)
前記負のチェックポイント調節因子が、細胞傷害性Tリンパ球関連タンパク質4(CTLA-4)、プログラム細胞死タンパク質1(PD-1)、リンパ球活性化遺伝子3(LAG-3)、T細胞免疫グロブリンムチン含有タンパク質3(TIM-3)、B及びTリンパ球減衰因子(BTLA)、Ig及びITIMドメインを有するT細胞免疫受容体(TIGIT)、T細胞活性化のVドメインIg抑制因子(VISTA)、アデノシンA2a受容体(A2aR)、キラー細胞免疫グロブリン様受容体(KIR)、インドールアミン2,3-ジオキシゲナーゼ(IDO)、CD20、CD39、ならびにCD73からなる群から選択される、項目54に記載のEV。
(項目56)
前記生物学的に活性な分子が、免疫原性タンパク質である、項目1~47のいずれか一項に記載のEV。
(項目57)
前記生物学的に活性な分子が、毒素、トキソイド、または毒素の非毒性変異体である、項目1~47のいずれか一項に記載のEV。
(項目58)
前記毒素が、ジフテリア毒素である、項目57に記載のEV。
(項目59)
前記トキソイドが、破傷風トキソイドである、項目57に記載のEV。
(項目60)
前記生物学的に活性な分子が、ジフテリア毒素の非毒性変異体である、項目57に記載のEV。
(項目61)
前記生物学的に活性な分子が、正の共刺激分子の活性化剤または正の共刺激分子の結合パートナーの活性化剤である、項目1~60のいずれか1項に記載のEV。
(項目62)
前記正の共刺激分子が、TNF受容体スーパーファミリーメンバーである、項目61に記載のEV。
(項目63)
前記TNF受容体スーパーファミリーメンバーが、CD120a、CD120b、CD18、OX40、CD40、Fas受容体、M68、CD27、CD30、4-1BB、TRAILR1、TRAILR2、TRAILR3、TRAILR4、RANK、OCIF、TWEAK受容体、TACI、BAFF受容体、ATAR、CD271、CD269、AITR、TROY、CD358、TRAMP、及びXEDARからなる群から選択される、項目62に記載のEV。
(項目64)
正の共刺激分子の前記活性化剤が、TNFスーパーファミリーメンバーである、項目63に記載のEV。
(項目65)
前記TNFスーパーファミリーメンバーが、TNFα、TNF-C、OX40L、CD40L、FasL、LIGHT、TL1A、CD27L、Siva、CD153、4-1BBリガンド、TRAIL、RANKL、TWEAK、APRIL、BAFF、CAMLG、NGF、BDNF、NT-3、NT-4、GITRリガンド、及びEDA-2からなる群から選択される、項目64に記載のEV。
(項目66)
前記正の共刺激分子が、CD28-スーパーファミリー共刺激分子である、項目61に記載のEV。
(項目67)
前記CD28-スーパーファミリー共刺激分子が、ICOSまたはCD28である、項目66に記載のEV。
(項目68)
正の共刺激分子の前記活性化剤が、ICOSL、CD80、またはCD86である、項目67に記載のEV。
(項目69)
前記サイトカインが、IL-2、IL-7、IL-10、IL-12、及びIL-15からなる群から選択される、項目50に記載のEV。
(項目70)
前記タンパク質が、T細胞受容体(TCR)、T細胞共受容体、主要組織適合性複合体(MHC)、ヒト白血球抗原(HLA)、またはそれらの誘導体を含む、項目48に記載のEV。
(項目71)
前記タンパク質が、腫瘍抗原を含む、項目48に記載のEV。
(項目72)
前記腫瘍抗原が、アルファ-フェトプロテイン(AFP)、がん胎児性抗原(CEA)、上皮腫瘍抗原(ETA)、ムチン1(MUC1)、Tn-MUC1、ムチン16(MUC16)、チロシナーゼ、メラノーマ関連抗原(MAGE)、腫瘍タンパク質p53(p53)、CD4、CD8、CD45、CD80、CD86、プログラム死リガンド1(PD-L1)、プログラム死リガンド2(PD-L2)、NY-ESO-1、PSMA、TAG-72、HER2、GD2、cMET、EGFR、メソテリン、VEGFR、アルファ-葉酸受容体、CE7R、IL-3、がん-精巣抗原、MART-1gp100、及びTNF関連アポトーシス誘導リガンドからなる群から選択される、項目71に記載のEV。
(項目73)
前記EVがエクソソームである、項目1~72のいずれか一項に記載のEV。
(項目74)
項目1~73のいずれか一項に記載のEV及び薬学的に許容される担体を含む、薬学的組成物。
(項目75)
項目1~73のいずれか一項に記載のEVを産生する細胞。
(項目76)
1つ以上のベクターを含む細胞であって、前記ベクターが、前記足場タンパク質及び項目1~73のいずれか一項に記載の生物学的に活性な分子をコードする核酸配列を含む、前記細胞。
(項目77)
前記核酸配列が、プロモーターに作用可能に結合している、項目76に記載の細胞。
(項目78)
項目1~73のいずれか一項に記載のEV及び使用説明書を含む、キット。
(項目79)
好適な条件下で項目75~77のいずれか一項に記載の細胞を培養し、前記EVを得ることを含む、EVの作製方法。
(項目80)
項目1~73のいずれか一項に記載の生物学的に活性な分子を項目1~73のいずれか一項に記載の足場タンパク質に連結することを含む、生物学的に活性な分子を細胞外小胞に固定する方法。
(項目81)
疾患の予防または治療を必要とする対象において前記疾患を予防または治療する方法であって、項目1~73のいずれか一項に記載のEVを投与することを含み、前記疾患は前記抗原と関連付けられる、前記方法。
(項目82)
前記EVが、非経口、経口、静脈内、筋肉内、腫瘍内、鼻腔内、皮下、または腹腔内で投与される、項目81に記載の方法。
The drawings show various aspects of the present disclosure for purposes of illustration only. Those skilled in the art will readily recognize from the following considerations that alternative embodiments of the structures and methods exemplified herein can be used without departing from the principles of the present disclosure described herein. Will.
In the embodiment of the present invention, for example, the following items are provided.
(Item 1)
An isolated extracellular vesicle (EV) containing a biologically active molecule linked to a scaffold protein, wherein the scaffold protein contains an N-terminal domain (ND) and an effector domain (ED), said ND. Associates with the lumen surface of the EV, the ED associates with the lumen surface of the EV by ionic interaction, and the ED comprises at least two contiguous lys in the sequence, said isolation. Extracellular vesicles (EV).
(Item 2)
The EV of item 1, wherein the ND associates with the lumen surface of the EV via myristoylation.
(Item 3)
The EV according to item 2, wherein the ND has Gly at the N-terminal.
(Item 4)
The EV according to any one of items 1 to 3, wherein the ED comprises at least 3 Lys, at least 4 Lys, at least 5 Lys, at least 6 Lys, or at least 7 Lys.
(Item 5)
The EV according to any one of items 1 to 4, wherein the ED is linked to the ND by a peptide bond.
(Item 6)
The EV according to item 4 or 5, wherein the ED comprises (Lys) n, where n is an integer of 1-10.
(Item 7)
The EV according to any one of items 1 to 6, wherein the ED comprises KK, KKK, KKK (SEQ ID NO: 151), KKKKK (SEQ ID NO: 152), or any combination thereof.
(Item 8)
The ND contains the amino acid sequence described in G: X2: X3: X4: X5: X6, G is a glycine represented as Gly, ":" represents a peptide bond, and the X2 to X6. The EV according to any one of items 1 to 7, wherein each is an independent amino acid and the X6 contains a basic amino acid.
(Item 9)
The EV according to item 8, wherein the X6 is selected from the group consisting of Lys, Arg, and His.
(Item 10)
An isolated extracellular vesicle (EV) containing a biologically active molecule linked to a scaffold protein, wherein the scaffold protein comprises an N-terminal domain (ND) and an effector domain (ED), said ND. Contains the amino acid sequence described in G: X2: X3: X4: X5: X6, where G is glycine represented by Gly, where ":" represents a peptide bond and each of X2 to X6 is independent. The isolated extracellular vesicle (EV), wherein the X6 contains a basic amino acid, the ED is linked to the X6 by peptide binding, and the N-terminus of the ED contains at least one lysine. ..
(Item 11)
The EV according to any one of items 1 to 10, wherein the ED does not contain a transmembrane domain or a cytoplasmic domain of a virus.
(Item 12)
The EV according to any one of items 8 to 11, wherein the X2 is selected from the group consisting of Pro, Gly, Ala, and Ser.
(Item 13)
The EV according to any one of items 8 to 12, wherein the X4 is selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Gln, and Met.
(Item 14)
The EV according to any one of items 8 to 13, wherein the X5 is selected from the group consisting of Pro, Gly, Ala, and Ser.
(Item 15)
The ND of the scaffold protein comprises the amino acid sequence of G: X2: X3: X4: X5: X6.
(I) G represents Gly and represents
(Ii) ":" represents a peptide bond,
(Iii) The X2 is an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser.
(Iv) The X3 is an amino acid,
(V) The X4 is an amino acid selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Gln, and Met.
(Vi) The X5 is an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser.
(Vii) The EV according to any one of items 1 to 14, wherein the X6 is an amino acid selected from the group consisting of Lys, Arg, and His.
(Item 16)
The EV according to any one of items 8 to 15, wherein the X3 is selected from the group consisting of Asn, Gln, Ser, Thr, Asp, Glu, Lys, His, and Arg.
(Item 17)
The EV according to any one of items 1 to 9 and 11 to 16, wherein the ND and the ED are bonded by a linker.
(Item 18)
17. The EV of item 17, wherein the linker comprises a peptide bond or one or more amino acids.
(Item 19)
An isolated extracellular vesicle (EV) containing a biologically active molecule linked to a scaffold protein, said scaffold protein comprising ND-ED.
a. ND includes G: X2: X3: X4: X5: X6,
i. G stands for Gly
ii. ":" Represents a peptide bond
iii. X2 is an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser.
iv. The X3 is an amino acid,
v. X4 is an amino acid selected from the group consisting of Pro, Gly, Ala, Ser, Val, Ile, Leu, Phe, Trp, Tyr, Glu, and Met.
vi. X5 is an amino acid selected from the group consisting of Pro, Gly, Ala, and Ser.
vii. X6 is an amino acid selected from the group consisting of Lys, Arg, and His.
b. "-" Is any linker containing one or more amino acids.
c. The ED comprises (i) at least two consecutive lysines linked to the X6 by a peptide bond or one or more amino acids, or (ii) at least one lysine directly linked to the X6 by a peptide bond. The isolated extracellular vesicle (EV), which is the effector domain.
(Item 20)
The EV according to any one of items 8 to 19, wherein X2 is selected from the group consisting of Gly and Ala.
(Item 21)
The EV according to any one of items 8 to 20, wherein X3 is Lys.
(Item 22)
The EV according to any one of items 8 to 21, wherein the X4 is Leu or Glu.
(Item 23)
The EV according to any one of items 8 to 22, wherein X5 is selected from the group consisting of Ser and Ala.
(Item 24)
The EV according to any one of items 8 to 23, wherein X6 is Lys.
(Item 25)
X2 is Gly, Ala, or Ser, X3 is Lys or Glu, X4 is Leu, Phe, Ser, and Glu, X5 is Ser or Ala, and X6. Is Lys, the EV according to any one of items 8 to 24.
(Item 26)
The EV according to any one of items 19 to 25, wherein the ND and the ED are linked by a linker containing one or more amino acids.
(Item 27)
The EV according to any one of items 19 to 26, wherein the ED comprises Lys (K), KK, KKK, KKK (SEQ ID NO: 151), KKKKK (SEQ ID NO: 152), or any combination thereof.
(Item 28)
The scaffold proteins are (i) GGKLSKK (SEQ ID NO: 157), (ii) GAKLSKK (SEQ ID NO: 158), (iii) GGKQSKK (SEQ ID NO: 159), (iv) GGKLAKK (SEQ ID NO: 160), or (v) them. The EV according to any one of items 1 to 27, which comprises an amino acid sequence selected from the group consisting of any combination of the above.
(Item 29)
The scaffold protein is (i) GGKLSKKK (SEQ ID NO: 161), (ii) GGKLSKKS (SEQ ID NO: 162), (iii) GAKLSKKK (SEQ ID NO: 163), (iv) GAKLSKKS (SEQ ID NO: 164), (v) GGKQSKK (v). SEQ ID NO: 165), (vi) GGKQSKKS (SEQ ID NO: 166), (vii) GGKLAKKK (SEQ ID NO: 167), (viii) GGKLAKKS (SEQ ID NO: 168), and (ix) selected from the group consisting of any combination thereof. 28. The EV of item 28, comprising the amino acid sequence.
(Item 30)
The scaffold protein is at least about 8, at least about 9, at least about 10, at least about 11, at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least. About 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55 At least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 105, at least about 110, at least about 120, at least The EV according to any one of items 1-29, which is about 130, at least about 140, at least about 150, at least about 160, at least about 170, at least about 180, at least about 190, or at least about 200 amino acids long.
(Item 31)
The scaffold protein is (i) GGKLSKKKKGYNVN (SEQ ID NO: 169), (ii) GAKLSKKKKGYNVN (SEQ ID NO: 170), (iii) GGKQSKKKKGYNVN (SEQ ID NO: 171), (iv) GGKLKKGYNVN. SEQ ID NO: 173), (vi) GGKLSKKKKGSGGS (SEQ ID NO: 174), (vii) GGKLSKKKSKSGSG (SEQ ID NO: 175), (viii) GGKLSKKGSGSG (SEQ ID NO: 176), (ix) GGKGSG (SEQ ID NO: 176), (ix) The EV according to any one of items 1 to 30, which comprises SEQ ID NO: 178) or (xi) GAKKSKRFSFKKS (SEQ ID NO: 179).
(Item 32)
The EV according to any one of items 1 to 31, wherein the scaffold protein does not contain Met at the N-terminal.
(Item 33)
The EV according to any one of items 1 to 32, wherein the scaffold protein contains a myristoylated amino acid residue at the N-terminal of the scaffold protein.
(Item 34)
33. The EV of item 33, wherein the amino acid residue at the N-terminus of the scaffold protein is Gly.
(Item 35)
The EV according to item 33 or 34, wherein the amino acid residue at the N-terminal of the scaffold protein is a synthetic substance.
(Item 36)
The EV according to item 33 or 35, wherein the amino acid residue at the N-terminus of the scaffold protein is a glycine analog.
(Item 37)
The scaffold protein is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90 with SEQ ID NO: 1 (MARKS), SEQ ID NO: 2 (MARKSL1), or SEQ ID NO: 3 (BASP1). %, At least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or any one of items 1-36 comprising an amino acid sequence having about 100% sequence identity. The EV described in the section.
(Item 38)
The EV according to any one of items 1 to 37, wherein the biologically active molecule is on the lumen surface or on the lumen of the EV.
(Item 39)
The EV according to any one of items 1 and 8, wherein the scaffold protein further comprises a transmembrane domain.
(Item 40)
39. EV, wherein the transmembrane domain is between the ED domain of the scaffold protein and the biologically active molecule.
(Item 41)
The EV according to any one of items 1 to 40, wherein the scaffold protein further comprises an extracellular domain.
(Item 42)
41. The EV of item 41, wherein the biologically active molecule is linked to the extracellular domain.
(Item 43)
The EV according to any one of items 1-42, wherein the scaffold protein is linked to the biologically active molecule by a linker.
(Item 44)
The EV according to any one of items 1-43, wherein the ND domain is linked to the ED domain by a linker.
(Item 45)
The EV according to item 43 or 44, wherein the linker comprises a peptide bond or one or more amino acids.
(Item 46)
The EV according to any one of items 17 to 19, 26, and 43 to 45, wherein the linker includes a cleavable linker.
(Item 47)
The EV according to any one of items 17 to 19, 26, and 43 to 45, wherein the linker includes a flexible linker.
(Item 48)
The biologically active molecule forms a protein, polypeptide, peptide, polynucleotide (DNA and / or RNA), chemical compound, virus, ionophore, carrier for ionophore, channel or pore, or any of them. The EV according to any one of items 1 to 47, which comprises any combination.
(Item 49)
28. EV according to item 48, wherein the protein comprises a recombinant peptide, a natural peptide, a synthetic peptide, an antibody, a fusion protein, or any combination thereof.
(Item 50)
28. EV according to item 48, wherein the protein comprises an enzyme, a cytokine, a ligand, a receptor, a transcription factor, or a combination thereof.
(Item 51)
28. EV according to item 48, wherein the virus comprises an adeno-associated virus, parvovirus, retrovirus, adenovirus, or any combination thereof.
(Item 52)
The EV according to any one of items 1 to 51, wherein the EV further comprises a second scaffold protein.
(Item 53)
The second scaffold protein is PTGFRN polypeptide, BSG polypeptide, IGSF2 polypeptide, IGSF3 polypeptide, IGSF8 polypeptide, ITGB1 polypeptide, ITGA4 polypeptide, SLC3A2 polypeptide, ATP transporter polypeptide, aminopeptidase N ( Item 52. ..
(Item 54)
The EV according to any one of items 1 to 53, wherein the biologically active molecule is an inhibitor of a negative checkpoint regulator or an inhibitor of a binding partner of a negative checkpoint regulator.
(Item 55)
The negative checkpoint regulators are cytotoxic T lymphocyte-related protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), lymphocyte activation gene 3 (LAG-3), and T cell immunity. Globulin Mutin-Containing Protein 3 (TIM-3), B and T Lymphocyte Attenuating Factor (BTLA), T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT), V Domain Ig Inhibitor of T Cell Activation (VISTA) 54, item 54, selected from the group consisting of adenosine A2a receptor (A2aR), killer cell immunoglobulin-like receptor (KIR), indolamine 2,3-dioxygenase (IDO), CD20, CD39, and CD73. EV.
(Item 56)
The EV according to any one of items 1 to 47, wherein the biologically active molecule is an immunogenic protein.
(Item 57)
The EV according to any one of items 1-47, wherein the biologically active molecule is a toxin, toxoid, or a non-toxic variant of the toxin.
(Item 58)
57. EV, wherein the toxin is a diphtheria toxin.
(Item 59)
58. The EV according to item 57, wherein the toxoid is a tetanus toxoid.
(Item 60)
57. EV according to item 57, wherein the biologically active molecule is a non-toxic variant of diphtheria toxin.
(Item 61)
The EV according to any one of items 1 to 60, wherein the biologically active molecule is an activator of a positive co-stimulator molecule or an activator of a binding partner of a positive co-stimulator molecule.
(Item 62)
The EV according to item 61, wherein the positive co-stimulator molecule is a member of the TNF receptor superfamily.
(Item 63)
The TNF receptor superfamily members include CD120a, CD120b, CD18, OX40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, RANK, OCIF, TWEK receptor, Taci. 62. EV according to item 62, selected from the group consisting of BAFF receptor, ATAR, CD271, CD269, AITR, TROY, CD358, TRAMP, and XEDAR.
(Item 64)
The EV according to item 63, wherein the activator of the positive co-stimulatory molecule is a member of the TNF superfamily.
(Item 65)
The TNF superfamily members include TNFα, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF. 64. EV according to item 64, selected from the group consisting of NT-3, NT-4, GITR ligand, and EDA-2.
(Item 66)
The EV according to item 61, wherein the positive co-stimulator is a CD28-superfamily co-stimulator.
(Item 67)
66. EV, wherein the CD28-superfamily co-stimulator molecule is ICOS or CD28.
(Item 68)
67. EV, wherein the activator of the positive co-stimulator molecule is ICOSL, CD80, or CD86.
(Item 69)
The EV according to item 50, wherein the cytokine is selected from the group consisting of IL-2, IL-7, IL-10, IL-12, and IL-15.
(Item 70)
28. EV according to item 48, wherein the protein comprises a T cell receptor (TCR), a T cell co-receptor, a major histocompatibility complex (MHC), a human leukocyte antigen (HLA), or a derivative thereof.
(Item 71)
28. EV, wherein the protein comprises a tumor antigen.
(Item 72)
The tumor antigens are alpha-fet protein (AFP), cancer fetal antigen (CEA), epithelial tumor antigen (ETA), mutin 1 (MUC1), Tn-MUC1, mutin 16 (MUC16), tyrosinase, melanoma-associated antigen ( MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG- Selected from the group consisting of 72, HER2, GD2, cMET, EGFR, mesothelin, VEGFR, alpha-folic acid receptor, CE7R, IL-3, cancer-testis antigen, MART-1gp100, and TNF-related apoptosis-inducing ligands. EV according to item 71.
(Item 73)
The EV according to any one of items 1 to 72, wherein the EV is an exosome.
(Item 74)
A pharmaceutical composition comprising the EV according to any one of items 1 to 73 and a pharmaceutically acceptable carrier.
(Item 75)
The cell that produces the EV according to any one of items 1 to 73.
(Item 76)
A cell comprising one or more vectors, wherein the vector comprises a nucleic acid sequence encoding the scaffold protein and the biologically active molecule according to any one of items 1-73.
(Item 77)
76. The cell of item 76, wherein the nucleic acid sequence is operably bound to a promoter.
(Item 78)
A kit comprising the EV and instruction manual according to any one of items 1 to 73.
(Item 79)
A method for producing an EV, which comprises culturing the cells according to any one of items 75 to 77 under suitable conditions to obtain the EV.
(Item 80)
Cell cells of a biologically active molecule comprising linking the biologically active molecule according to any one of items 1 to 73 to the scaffold protein according to any one of items 1 to 73. How to fix to the outer vesicles.
(Item 81)
A method of preventing or treating a disease in a subject in need of prevention or treatment of the disease, comprising administering the EV according to any one of items 1-73, wherein the disease is associated with the antigen. The above method.
(Item 82)
81. The method of item 81, wherein the EV is administered parenterally, orally, intravenously, intramuscularly, intratumorally, intranasally, subcutaneously, or intraperitoneally.
Claims (27)
前記足場タンパク質はN末端ドメイン(ND)及びエフェクタードメイン(ED)を含み、
前記NDは前記EVの内腔表面と会合し、前記EDはイオン相互作用によって前記EVの前記内腔表面と会合し、
前記NDは、GGKLSK(配列番号203)のアミノ酸配列を含むが、N末端にメチオニン(Met)を含まず、
前記EDは、前記NDの配列番号203のC末端のリジンに直接連結したリジン(Lys)をそのN末端に含む、
前記単離された細胞外小胞(EV)。 An isolated extracellular vesicle (EV) containing a biologically active molecule linked to a scaffold protein.
The scaffold protein contains an N-terminal domain (ND) and an effector domain (ED).
The ND associates with the luminal surface of the EV, and the ED associates with the luminal surface of the EV by ion interaction.
The ND contains the amino acid sequence of GGKLSK (SEQ ID NO: 203), but does not contain methionine (Met) at the N-terminus.
The ED contains a lysine (Lys) directly linked to the C-terminal lysine of SEQ ID NO: 203 of the ND at its N-terminal .
The isolated extracellular vesicle (EV).
(i)膜貫通ドメイン、
(ii)小胞外ドメイン、または
(iii)(i)および(ii)の両方
をさらに含む、請求項1に記載のEV。 The scaffold protein
(I) Transmembrane domain ,
(Ii) Extravesicular domain, or
(Iii) Both (i) and (ii)
The EV according to claim 1 , further comprising.
(i)前記膜貫通ドメインが、前記足場タンパク質のEDドメインと前記生物学的に活性な分子との間にあり、
(ii)前記生物学的に活性な分子が、前記小胞外ドメインに連結される、
請求項1に記載のEV。 The scaffold protein further comprises a transmembrane domain and an extracellular domain.
(I) The transmembrane domain is between the ED domain of the scaffold protein and the biologically active molecule .
(Ii) The biologically active molecule is linked to the extracellular domain.
The EV according to claim 1 .
(a)タンパク質、
(b)ポリペプチド;
(c)ペプチド;
(d)ポリヌクレオチド(DNA及び/またはRNA);
(e)化学化合物;
(f)ウイルス;
(g)イオノフォア;
(h)イオノフォア用担体;
(i)チャネルもしくは細孔を形成する部分;または
(j)それらの任意の組み合わせ
を含む、請求項1~13のいずれか一項に記載のEV。 The biologically active molecule
(A) Protein,
(B) Polypeptide ;
(C) Peptide ;
(D) Polynucleotide (DNA and / or RNA) ;
(E) Chemical compound ;
(F) Virus ;
(G) Ionophore ;
(H) Ionophore carrier ;
(I) The part forming the channel or pore ; or
(J) The EV according to any one of claims 1 to 13 , which comprises any combination thereof.
(i)組換えペプチド、天然ペプチド、合成ペプチド、抗体、融合タンパク質、またはそれらの任意の組み合わせ
(ii)酵素、サイトカイン、リガンド、受容体、転写因子、またはそれらの組み合わせ;
(iii)T細胞受容体(TCR)、T細胞共受容体、主要組織適合性複合体(MHC)、ヒト白血球抗原(HLA)、またはそれらの誘導体;あるいは
(iv)腫瘍抗原であって、必要に応じて、アルファ-フェトプロテイン(AFP)、がん胎児性抗原(CEA)、上皮腫瘍抗原(ETA)、ムチン1(MUC1)、Tn-MUC1、ムチン16(MUC16)、チロシナーゼ、メラノーマ関連抗原(MAGE)、腫瘍タンパク質p53(p53)、CD4、CD8、CD45、CD80、CD86、プログラム死リガンド1(PD-L1)、プログラム死リガンド2(PD-L2)、NY-ESO-1、PSMA、TAG-72、HER2、GD2、cMET、EGFR、メソテリン、VEGFR、アルファ-葉酸受容体、CE7R、IL-3、がん-精巣抗原、MART-1gp100、及びTNF関連アポトーシス誘導リガンドからなる群から選択される腫瘍抗原
を含む、請求項14に記載のEV。 The protein
(I) Recombinant peptides, natural peptides, synthetic peptides, antibodies, fusion proteins, or any combination thereof.
(Ii) Enzymes, cytokines, ligands, receptors, transcription factors, or combinations thereof;
(Iii) T cell receptor (TCR), T cell co-receptor, major histocompatibility complex (MHC), human leukocyte antigen (HLA), or derivatives thereof; or
(Iv) Tumor antigens, as needed, alpha-apoptotic protein (AFP), cancer fetal antigen (CEA), epithelial tumor antigen (ETA), mutin 1 (MUC1), Tn-MUC1, mutin 16 ( MUC16), tyrosinase, melanoma-related antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), NY -ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, mesothelin, VEGFR, alpha-folic acid receptor, CE7R, IL-3, cancer-testile antigen, MART-1gp100, and TNF-related apoptosis induction Tumor antigen selected from the group consisting of ligands
The EV according to claim 14 , wherein the EV comprises.
(a)負のチェックポイント調節因子の阻害剤または負のチェックポイント調節因子の結合パートナーの阻害剤であり、ここで、前記負のチェックポイント調節因子は、必要に応じて、
(i)細胞傷害性Tリンパ球関連タンパク質4(CTLA-4)、
(ii)プログラム細胞死タンパク質1(PD-1)、
(iii)リンパ球活性化遺伝子3(LAG-3)、
(iv)T細胞免疫グロブリンムチン含有タンパク質3(TIM-3)、
(v)B及びTリンパ球減衰因子(BTLA)、
(vi)Ig及びITIMドメインを有するT細胞免疫受容体(TIGIT)、
(vii)T細胞活性化のVドメインIg抑制因子(VISTA)、
(viii)アデノシンA2a受容体(A2aR)、
(ix)キラー細胞免疫グロブリン様受容体(KIR)、
(x)インドールアミン2,3-ジオキシゲナーゼ(IDO)、
(xi)CD20、
(xii)CD39、および
(xiii)CD73
からなる群から選択される;
(b)免疫原性タンパク質である;
(c)毒素、トキソイド、または毒素の非毒性変異体であり、ここで、
(i)前記毒素は必要に応じてジフテリア毒素である、または
(ii)前記トキソイドは必要に応じて破傷風トキソイドである;あるいは
(d)正の共刺激分子の活性化剤または正の共刺激分子の結合パートナーの活性化剤であり、ここで、前記正の共刺激分子は、必要に応じて、
(i)TNF受容体スーパーファミリーメンバーであって、必要に応じて、CD120a、CD120b、CD18、OX40、CD40、Fas受容体、M68、CD27、CD30、4-1BB、TRAILR1、TRAILR2、TRAILR3、TRAILR4、RANK、OCIF、TWEAK受容体、TACI、BAFF受容体、ATAR、CD271、CD269、AITR、TROY、CD358、TRAMP、及びXEDARからなる群から選択され、必要に応じてここで、正の共刺激分子の前記活性化剤は、TNFスーパーファミリーメンバーであり、必要に応じて、TNFα、TNF-C、OX40L、CD40L、FasL、LIGHT、TL1A、CD27L、Siva、CD153、4-1BBリガンド、TRAIL、RANKL、TWEAK、APRIL、BAFF、CAMLG、NGF、BDNF、NT-3、NT-4、GITRリガンド、及びEDA-2からなる群から選択される、TNF受容体スーパーファミリーメンバー;ならびに
(ii)CD28-スーパーファミリー共刺激分子であって、必要に応じて、ICOS及びCD28から選択され、必要に応じてここで、正の共刺激分子の前記活性化剤は、ICOSL、CD80、またはCD86である、CD28-スーパーファミリー共刺激分子
からなる群から選択される、
請求項1~17のいずれか1項に記載のEV。 The biologically active molecule
(A) an inhibitor of a negative checkpoint regulator or an inhibitor of a binding partner of a negative checkpoint regulator, wherein the negative checkpoint regulator is optionally.
(I) Cytotoxic T lymphocyte-related protein 4 (CTLA-4),
(Ii) Programmed cell death protein 1 (PD-1),
(Iii) Lymphocyte activation gene 3 (LAG-3),
(Iv) T cell immunoglobulin mucin-containing protein 3 (TIM-3),
(V) B and T lymphocyte attenuating factor (BTLA),
(Vi) T cell immune receptor (TIGIT) with Ig and ITIM domains,
(Vii) V-domain Ig inhibitor (VISTA) for T cell activation,
(Viii) Adenosine A2a receptor (A2aR),
(Ix) Killer Cell Immunoglobulin-like Receptor (KIR),
(X) Indoleamine 2,3-dioxygenase (IDO),
(Xi) CD20,
(Xii) CD39, and
(Xiii) CD73
Selected from the group consisting of;
(B) An immunogenic protein;
(C) Toxins, toxoids, or non-toxic variants of toxins, where
(I) The toxin is, if necessary, a diphtheria toxin, or
(Ii) The toxoid is, if necessary, a tetanus toxoid;
(D) An activator of a positive co-stimulator molecule or an activator of a binding partner of a positive co-stimulator molecule, wherein the positive co-stimulator molecule is, if necessary.
(I) TNF receptor superfamily members, CD120a, CD120b, CD18, OX40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, as needed. Selected from the group consisting of RANK, OCIF, TWEAK receptor, TACI, BAFF receptor, ATAR, CD271, CD269, AITR, TROY, CD358, TRAMP, and XEDAR, where the positive costimulatory molecule is optionally. The activator is a TNF superfamily member and, if necessary, TNFα, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK. , APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR ligands, and TNF receptor superfamily members selected from the group consisting of EDA-2;
(Ii) A CD28-superfamily co-stimulator, optionally selected from ICOS and CD28, wherein the activator of the positive co-stimulator is ICOSL, CD80, or, optionally. CD28-superfamily co-stimulatory molecule, CD86
Selected from a group of
The EV according to any one of claims 1 to 17 .
The pharmaceutical composition comprising EV according to any one of claims 1 to 20 , for preventing or treating the disease in a subject in need of prevention or treatment of the disease.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2018/061679 WO2019099942A1 (en) | 2017-11-17 | 2018-11-16 | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
USPCT/US2018/061679 | 2018-11-16 | ||
US201962835430P | 2019-04-17 | 2019-04-17 | |
US62/835,430 | 2019-04-17 | ||
PCT/US2019/033629 WO2020101740A1 (en) | 2018-11-16 | 2019-05-22 | Engineered extracellular vesicles and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513049A JP2022513049A (en) | 2022-02-07 |
JPWO2020101740A5 true JPWO2020101740A5 (en) | 2022-05-31 |
Family
ID=70732111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021526563A Pending JP2022513049A (en) | 2018-11-16 | 2019-05-22 | Manipulated extracellular vesicles and their use |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP3672614B1 (en) |
JP (1) | JP2022513049A (en) |
KR (1) | KR20210098473A (en) |
CN (1) | CN113286603A (en) |
AU (1) | AU2019378591A1 (en) |
BR (1) | BR112021009231A2 (en) |
CA (1) | CA3119720A1 (en) |
CL (1) | CL2021001278A1 (en) |
CY (1) | CY1124897T1 (en) |
DK (1) | DK3672614T3 (en) |
EA (1) | EA202191334A1 (en) |
ES (1) | ES2907967T3 (en) |
HR (1) | HRP20220020T1 (en) |
HU (1) | HUE057300T2 (en) |
IL (1) | IL283167A (en) |
LT (1) | LT3672614T (en) |
MA (1) | MA49971B1 (en) |
MD (1) | MD3672614T2 (en) |
MX (1) | MX2021005636A (en) |
PH (1) | PH12021551088A1 (en) |
PL (1) | PL3672614T3 (en) |
PT (1) | PT3672614T (en) |
RS (1) | RS62863B1 (en) |
SG (1) | SG11202104956QA (en) |
SI (1) | SI3672614T1 (en) |
TW (1) | TW202038993A (en) |
WO (1) | WO2020101740A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220009389A (en) * | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | Composition of exosomes and AAV |
WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
BR112022002691A2 (en) * | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | EXTRACELLULAR ASO VESICLE CONSTRUCTS AIMING STAT6 |
WO2021030768A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
JP2022544288A (en) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | Extracellular vesicle-ASO constructs targeting CEBP/β |
CA3147701A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
WO2021062060A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
JP2023517992A (en) | 2020-03-12 | 2023-04-27 | インスティチュート フォー ベーシック サイエンス | Cell death-inducing composition having genome sequence mutation and cell death-inducing method using said composition |
WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
WO2021189047A2 (en) | 2020-03-20 | 2021-09-23 | Codiak Biosciences, Inc. | Extracellular vesicles for therapy |
US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
AU2021320419A1 (en) * | 2020-08-07 | 2023-03-09 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
CA3193107A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
GB202015399D0 (en) * | 2020-09-29 | 2020-11-11 | Evox Therapeutics Ltd | Engineered extracellular vesicles displaying enhanced pharmacokinetics |
WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
CN112410304A (en) * | 2020-11-12 | 2021-02-26 | 天津大学 | Gene-modified exosome and preparation method and application thereof |
CN112899307A (en) * | 2021-01-28 | 2021-06-04 | 苏州大学 | Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors |
KR20230157346A (en) | 2021-02-17 | 2023-11-16 | 론자 세일즈 아게 | Method for loading extracellular vesicles |
IL305171A (en) * | 2021-02-17 | 2023-10-01 | Lonza Sales Ag | Extracellular vesicle-nlrp3 antagonist |
CN117120041A (en) | 2021-04-01 | 2023-11-24 | 隆萨销售股份有限公司 | Extracellular vesicle compositions |
CN114057893B (en) * | 2021-04-26 | 2022-12-30 | 苏州大学 | Myristoylation polypeptide for encoding mitochondrial localization and preparation method and application thereof |
CN117126886A (en) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | Nucleic acid construct for realizing modular loading of engineering EVs functional proteins and application thereof |
WO2023229366A1 (en) * | 2022-05-24 | 2023-11-30 | Shiftbio Co., Ltd. | Surface-engineered extracellular vesicles and therapeutic uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US20110003008A1 (en) * | 2008-02-22 | 2011-01-06 | Agency For Science, Technology And Research (A*Star) | Mesenchymal stem cell particles |
FR2950350B1 (en) | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | NOVEL POLYNUCLEOTIDES AND CHIMERIC POLYPEPTIDES FOR THE SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND USES THEREOF |
WO2016138525A1 (en) * | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
US10617768B2 (en) * | 2016-07-12 | 2020-04-14 | Santa Clara University | Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins |
US20210290556A1 (en) * | 2016-08-22 | 2021-09-23 | Codiak Biosciences, Inc. | Methods of suppressing delivery of exosomes to liver and spleen |
US20200025685A1 (en) * | 2016-12-15 | 2020-01-23 | Codiak Biosciences, Inc. | Methods of measuring exosomes using intrinsic fluorescence |
WO2019040920A1 (en) | 2017-08-25 | 2019-02-28 | Codiak Biosciences, Inc. | Preparation of therapeutic exosomes using membrane proteins |
US20200347112A1 (en) * | 2017-11-17 | 2020-11-05 | Codiak Biosciences, Inc. | Compositions of engineered exosomes and methods of loading luminal exosomes pay-loads |
EP3841112A1 (en) * | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
-
2019
- 2019-05-22 PT PT197310279T patent/PT3672614T/en unknown
- 2019-05-22 HU HUE19731027A patent/HUE057300T2/en unknown
- 2019-05-22 DK DK19731027.9T patent/DK3672614T3/en active
- 2019-05-22 BR BR112021009231-5A patent/BR112021009231A2/en unknown
- 2019-05-22 PL PL19731027T patent/PL3672614T3/en unknown
- 2019-05-22 SI SI201930182T patent/SI3672614T1/en unknown
- 2019-05-22 EP EP19731027.9A patent/EP3672614B1/en active Active
- 2019-05-22 CA CA3119720A patent/CA3119720A1/en active Pending
- 2019-05-22 MX MX2021005636A patent/MX2021005636A/en unknown
- 2019-05-22 RS RS20220009A patent/RS62863B1/en unknown
- 2019-05-22 EA EA202191334A patent/EA202191334A1/en unknown
- 2019-05-22 MD MDE20200694T patent/MD3672614T2/en unknown
- 2019-05-22 KR KR1020217018358A patent/KR20210098473A/en active Search and Examination
- 2019-05-22 JP JP2021526563A patent/JP2022513049A/en active Pending
- 2019-05-22 WO PCT/US2019/033629 patent/WO2020101740A1/en unknown
- 2019-05-22 AU AU2019378591A patent/AU2019378591A1/en active Pending
- 2019-05-22 EP EP21200884.1A patent/EP4059510A1/en active Pending
- 2019-05-22 SG SG11202104956QA patent/SG11202104956QA/en unknown
- 2019-05-22 ES ES19731027T patent/ES2907967T3/en active Active
- 2019-05-22 LT LTEPPCT/US2019/033629T patent/LT3672614T/en unknown
- 2019-05-22 HR HRP20220020TT patent/HRP20220020T1/en unknown
- 2019-05-22 CN CN201980083366.0A patent/CN113286603A/en active Pending
- 2019-05-22 MA MA49971A patent/MA49971B1/en unknown
- 2019-05-23 TW TW108117910A patent/TW202038993A/en unknown
-
2021
- 2021-05-11 PH PH12021551088A patent/PH12021551088A1/en unknown
- 2021-05-13 IL IL283167A patent/IL283167A/en unknown
- 2021-05-14 CL CL2021001278A patent/CL2021001278A1/en unknown
-
2022
- 2022-01-07 CY CY20221100020T patent/CY1124897T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020101740A5 (en) | ||
JP7295325B2 (en) | Heterodimers, homodimers and pharmaceutical compositions | |
HRP20220020T1 (en) | Engineered extracellular vesicles and uses thereof | |
US11702461B2 (en) | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides | |
KR20180132070A (en) | T-cell modulated multimeric polypeptides and methods for their use | |
KR20180132663A (en) | T-cell modulated multimeric polypeptides and methods for their use | |
JP2021500855A (en) | Antigen-presenting polypeptides and how to use them | |
US20220105162A1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
WO2021030153A2 (en) | Engineered t cell receptors and uses thereof | |
JP2022515330A (en) | Multimer T cell regulatory polypeptide and how to use it | |
KR20230009872A (en) | Multimeric T-Cell Regulatory Polypeptides and Methods of Use Thereof | |
US20230414777A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | |
US20230218731A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | |
EP4157349A1 (en) | Antigen presenting polypeptide complexes and methods of use thereof | |
US20230241192A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
KR20240007815A (en) | Anti-BDCA-2 Antibody and Use Thereof |